Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Average Target Price of $22.29 According to Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $22.29.

Several research firms have weighed in on ARCT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Thursday, October 15th. Leerink Partners boosted their price target on shares of Arcturus Therapeutics from $13.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, October 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. BTIG Research lowered their price objective on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, September 24th. Finally, Citigroup raised Arcturus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $8.00 to $20.00 in a research note on Thursday, September 24th.

Institutional Trading of Arcturus Therapeutics

Institutional investors have recently modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. boosted its position in Arcturus Therapeutics by 12.9% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,671,000 after acquiring an additional 262,347 shares during the last quarter. Amova Asset Management Americas Inc. grew its stake in shares of Arcturus Therapeutics by 12.9% during the 1st quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after acquiring an additional 262,347 shares in the last quarter. BlackRock Inc. bought a new position in shares of Arcturus Therapeutics during the 2nd quarter worth approximately $17,566,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Arcturus Therapeutics by 23.8% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 346,207 shares of the biotechnology company’s stock valued at $2,327,000 after purchasing an additional 66,528 shares during the last quarter. Finally, Heartland Advisors Inc. acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at approximately $1,976,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Stock Down 9.2%

ARCT stock opened at $11.03 on Friday. Arcturus Therapeutics has a twelve month low of $5.50 and a twelve month high of $17.96. The company has a market cap of $313.47 million, a P/E ratio of -3.33 and a beta of 2.48. The business has a fifty day moving average of $13.61 and a 200-day moving average of $8.99.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.16. The business had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. As a group, equities research analysts anticipate that Arcturus Therapeutics will post -3.48 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.